Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This study will compare the effectiveness, cost-effectiveness and direct healthcare costs of
asthma management in patients with evidence of persistent asthma following an increase in
asthma therapy in the form of either an increased dose of inhaled glucocorticosteroids (ICS)
using extrafine hydrofluoroalkane-beclometasone dipropionate (HFA-BDP) via pressurised
metered-dose inhaler (pMDI) or breath-actuated inhaler (BAI), or a change to combination ICS
plus long-acting bronchodilator (LABA) therapy using fixed combinations (fluticasone
propionate / salmeterol [FP/SAL] or budesonide / formoterol [BUD/FOR]) or separate pMDIs and
BAIs.
Details
Lead Sponsor:
Research in Real-Life Ltd
Collaborators:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries